Citi views yesterday’s selloff in shares of Larimar Therapeutics (LRMR) as a buying opportunity. Larimar announced that the FDA recommended the safety database for nomlabofusp include at least 30 patients with continuous exposure for six months, including a subset of at least 10 patients for one year, with the large majority receiving the 50mg dose, the analyst tells investors in a research note. The firm says that with full FDA alignment in hand, Larimar has a clear path to application submission, which is now guided for Q2 of 2026 versus the second half of 2025 previously, to allow for additional time to collect one year of safety follow-up for patients. Citi keeps a Buy rating on the shares with a $14 price target
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Larimar Therapeutics Updates on Nomlabofusp Progress
- Larimar Therapeutics: FDA Guidance Boosts Buy Rating Amid Promising Regulatory Progress
- Larimar Therapeutics Receives FDA Guidance for BLA Submission
- Larimar announces FDA safety database recommendations for nomlabofusp BLA
- Larimar to trade down on delayed FDA submission, says JonesResearch